-
公开(公告)号：CA2953472C
公开(公告)日：2022-08-02
申请号：CA2953472
申请日：2015-06-26
Applicant: UBE INDUSTRIES
Inventor： IWASE NORIAKI , NISHIDA HIROSHI , OKUDO MAKOTO , ITO MASAAKI , KONO SHIGEYUKI , MATOYAMA MASAAKI , USHIYAMA SHIGERU , OKANARI EIJI , MATSUNAGA HIROFUMI , NISHIKAWA KENJI , KIMURA TOMIO
IPC: C07D333/36 , A61K31/381 , A61P13/00 , A61P19/04 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00
Abstract: The invention provides a novel a-halogen-substituted thiophene compound salt that has a potent LPA receptor antagonistic action and is useful as a medicament. The salt is represented by the general formula (I): (wherein R is a hydrogen atom or a methoxy group; X is a halogen atom; A is selected from the group consisting of: ;M is an alkali metal or an alkaline earth metal; and n is 1 when M is an alkali metal and is 2 when M is an alkaline earth metal).
-
42.发明专利
公开(公告)号：DK3360869T3
公开(公告)日：2020-10-12
申请号：DK18157384
申请日：2013-12-27
Applicant: UBE INDUSTRIES
Inventor： IWASE NORIAKI , NISHIDA HIROSHI , OKUDO MAKOTO , ITO MASAAKI , KONO SHIGEYUKI , MATOYAMA MASAAKI , USHIYAMA SHIGERU , OKANARI EIJI , MATSUNAGA HIROFUMI , NISHIKAWA KENJI , KIMURA TOMIO
IPC: C07D333/36 , A61K31/381 , A61K31/427 , A61K31/443 , A61P13/00 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/02 , A61P43/00 , C07D409/04 , C07D409/14 , C07D417/12
-
公开(公告)号：CA2896701C
公开(公告)日：2020-10-06
申请号：CA2896701
申请日：2013-12-27
Applicant: UBE INDUSTRIES
Inventor： IWASE NORIAKI , NISHIDA HIROSHI , OKUDO MAKOTO , ITO MASAAKI , KONO SHIGEYUKI , MATOYAMA MASAAKI , USHIYAMA SHIGERU , OKANARI EIJI , MATSUNAGA HIROFUMI , NISHIKAWA KENJI , KIMURA TOMIO
IPC: C07D333/36 , A61K31/381 , A61K31/427 , A61K31/443 , A61P13/00 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D409/04 , C07D409/14 , C07D417/12
Abstract: The present invention provides a novel a-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament. In particular embodiments, the present invention provides a compound represented by the general formula (I) wherein A represents, a phenyl ring, a thiophene ring, or an isothiazole ring; R1 is the same or different, and represents a halogen atom, or a C1-C3 alkyl group; R2 represents a hydrogen atom, or a C1-C6 alkyl group; p represents an integer of 0 to 5; V represents CR3 wherein R3 represents a hydrogen atom, an amino group, a nitro group, or a C1-C3 alkoxy group, or V represents a nitrogen atom; and X represents a halogen atom, or a salt thereof. (see formula I)
-
公开(公告)号：AU2015281021B9
公开(公告)日：2019-03-28
申请号：AU2015281021
申请日：2015-06-26
Applicant: UBE INDUSTRIES
Inventor： IWASE NORIAKI , NISHIDA HIROSHI , OKUDO MAKOTO , ITO MASAAKI , KONO SHIGEYUKI , MATOYAMA MASAAKI , USHIYAMA SHIGERU , OKANARI EIJI , MATSUNAGA HIROFUMI , NISHIKAWA KENJI , KIMURA TOMIO
IPC: C07D333/36 , A61K31/381 , A61P13/00 , A61P19/04 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00
Abstract: Provided is a novel salt of an α-halogen-substituted thiophene compound that has powerful LPA receptor antagonistic action and that is useful as a pharmaceutical product. A salt represented by general formula (1) [In the formula: R is a hydrogen atom or a methoxy group; X is a halogen atom; A is a group selected from the group consisting of the following groups: (AA); M is an alkali metal or an alkali earth metal; and n is 1 when M is an alkali metal, and 2 when M is an alkali earth metal].
-
公开(公告)号：ES2667798T3
公开(公告)日：2018-05-14
申请号：ES13868493
申请日：2013-12-27
Applicant: UBE INDUSTRIES
Inventor： IWASE NORIAKI , NISHIDA HIROSHI , OKUDO MAKOTO , ITO MASAAKI , KONO SHIGEYUKI , MATOYAMA MASAAKI , USHIYAMA SHIGERU , OKANARI EIJI , MATSUNAGA HIROFUMI , NISHIKAWA KENJI , KIMURA TOMIO
IPC: C07D333/36 , A61K31/381 , A61K31/427 , A61K31/443 , A61P13/00 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D409/04 , C07D409/14 , C07D417/12
Abstract: Un compuesto representado por la fórmula general (I): [Fórmula química 320]**Fórmula** en donde A representa, un anillo de fenilo, un anillo de tiofeno o un anillo de isotiazol; R1 es el mismo o diferente, y representa un átomo de halógeno o un grupo alquilo de C1-C3; R2 representa un átomo de hidrógeno, o un grupo alquilo de C1-C6; p representa un entero de 0 a 5; V representa CR3 en donde R3 representa un átomo de hidrógeno, un grupo amino, un grupo nitro o un grupo alcoxi de C1-C3, o V representa un átomo de nitrógeno; X representa un átomo de halógeno, o una sal farmacológicamente aceptable del mismo.
-
Patent Agency Ranking
公开(公告)号：DK2940013T3
公开(公告)日：2018-03-26
申请号：DK13868493
申请日：2013-12-27
Applicant: UBE INDUSTRIES
Inventor： IWASE NORIAKI , NISHIDA HIROSHI , OKUDO MAKOTO , ITO MASAAKI , KONO SHIGEYUKI , MATOYAMA MASAAKI , USHIYAMA SHIGERU , OKANARI EIJI , MATSUNAGA HIROFUMI , NISHIKAWA KENJI , KIMURA TOMIO
IPC: C07D333/36 , A61K31/381 , A61K31/427 , A61K31/443 , A61P13/00 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/02 , A61P43/00 , C07D409/04 , C07D409/14 , C07D417/12
-
公开(公告)号：AU2016281225A1
公开(公告)日：2018-02-01
申请号：AU2016281225
申请日：2016-06-14
Applicant: UBE INDUSTRIES
Inventor： IWASE NORIAKI , AGA YASUHIRO , USHIYAMA SHIGERU , KONO SHIGEYUKI , SUNAMOTO HIDETOSHI , MATSUSHITA TAKASHI , OGI SAYAKA , UMEZAKI SATOSHI , KOJIMA MASAHIRO , ONUMA KAZUHIRO , SHIRAISHI YUSUKE , OKUDO MAKOTO , KIMURA TOMIO
IPC: C07F7/10 , A61K31/695 , A61P1/04 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/00 , A61P43/00 , C07F7/12
Abstract: The present invention provides a compound represented by general formula (Ia) or a pharmacologically acceptable salt thereof. In general formula (Ia), the two R each independently represent a C
-
公开(公告)号：BR112013000389A2
公开(公告)日：2016-06-07
申请号：BR112013000389
申请日：2011-07-08
Applicant: DAIICHI SANKYO CO LTD , UBE INDUSTRIES
Inventor： SHIMA AKIKO , NAMIKI HIDERONI , SUNAMOTO HIDETOSHI , SETOGUCHI HIROYUKI , TAKATA KATSUNORI , TSUBOIKE KAZUNARI , YONEDA KENJI , ITO KOJI , HAGIHARA MASAHIKO , TERASAKA NAOKI , IWASE NORIAKI , KIKUCHI OSAMU , NAKAMURA TSUYOSHI
IPC: C07D401/14 , A61K31/506 , A61K31/5377 , A61K31/541 , A61P3/04 , A61P3/06 , A61P9/10 , A61P43/00
Abstract: composto, composição farmacêutica, medicamento para inibir o cetp, medicamentos para aumentar a concentração o colesterol de hdl, e para diminuir a concentração do colesterol de ldl, uso do composto, e, método de tratamento ou profilaxia de uma doença. é divulgado um composto de piridina substituído que tem atividade de inibição de cetp excelente e é útil como um produto farmacêutico ou um sal deste farmaceuticamente aceitável. especificamente é divulgado um composoto, etc., que satisfaz a fórmula geral (i) (em que r^ 1^ é h, alquila substituível, oh, alcóxi opcionalmente substituído, alquilsulfonila, amino opcionalmente substituído, carbóxi, carbonila opcionalmente substituído, cn, halogênio, fenila opcionalmente substituído, heterociclila aromático opcionalmente substituído, heterociclila saturado opcionalmente substituído, heterociclilóxi saturado opcionalmente substituído, heterociclicarbonila saturado opcionalmente substituído, etc.)
-
公开(公告)号：AU2014312704A1
公开(公告)日：2016-04-14
申请号：AU2014312704
申请日：2014-09-02
Applicant: UBE INDUSTRIES
Inventor： YONEDA KENJI , SHIBAKAWA NOBUHIKO , KATSUBE TETSUSHI , KANDA TOMOKO , ITO KOJI , YAMAMOTO KIYOSHI , SHINOHARA MASARU , IWASE NORIAKI , USHIYAMA SHIGERU
IPC: A61K31/44 , A61K31/4436 , A61K31/444 , A61P11/00
Abstract: Provided is a pharmaceutical composition containing, as an active ingredient, a substituted biaryl compound represented by general formula (I) (where R
-
公开(公告)号：CA2923016A1
公开(公告)日：2015-03-05
申请号：CA2923016
申请日：2014-09-02
Applicant: UBE INDUSTRIES
Inventor： YONEDA KENJI , SHIBAKAWA NOBUHIKO , KATSUBE TETSUSHI , KANDA TOMOKO , ITO KOJI , YAMAMOTO KIYOSHI , SHINOHARA MASARU , IWASE NORIAKI , USHIYAMA SHIGERU
IPC: A61K31/44 , A61K31/4436 , A61K31/444 , A61P11/00
Abstract: Provided is a pharmaceutical composition containing, as an active ingredient, a substituted biaryl compound represented by general formula (I) (where R1, W, R2, and Z are each as defined in the claims and the description), or a pharmaceutically acceptable salt thereof. The pharmaceutical composition according to the present invention exhibits a superior anti-inflammatory effect, and is effective as a drug and/or prophylactic against chronic obstructive pulmonary disease.
-
-
-
-
-
-
-
-
-
Search Results
63
records
(took 0.027 seconds)
